Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830046, China.
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830046, China.
Biomed Pharmacother. 2024 Sep;178:117119. doi: 10.1016/j.biopha.2024.117119. Epub 2024 Aug 13.
Multidrug resistance (MDR) of tumors is one of the main reasons for the failure of chemotherapy. Multidrug resistance refers to the cross-resistance of tumor cells to multiple antitumor drugs with different structures and mechanisms of action. Current strategies to reverse multidrug resistance in tumors include MDR inhibitors and RNAi technology. siRNA is a small molecule RNA that is widely used in RNAi technology and has the characteristics of being prepared in large quantities and chemically modified. However, siRNA is susceptible to degradation in vivo. The effect of siRNA therapy alone is not ideal, so siRNA and anticancer drugs are administered in combination to reverse the MDR of tumors. Non-viral vectors are now commonly used to deliver siRNA and anticancer drugs to tumor sites. This article will review the progress of siRNA and chemotherapeutic drug delivery systems and their mechanisms for reversing multidrug resistance.
肿瘤的多药耐药性（MDR）是化疗失败的主要原因之一。多药耐药性是指肿瘤细胞对多种结构和作用机制不同的抗肿瘤药物的交叉耐药性。目前逆转肿瘤多药耐药性的策略包括 MDR 抑制剂和 RNAi 技术。siRNA 是一种小分子 RNA，广泛应用于 RNAi 技术，具有大量制备和化学修饰的特点。然而，siRNA 在体内易降解。siRNA 单独治疗的效果并不理想，因此 siRNA 和抗癌药物联合给药以逆转肿瘤的 MDR。非病毒载体现在常用于将 siRNA 和抗癌药物递送到肿瘤部位。本文将综述 siRNA 和化疗药物递药系统及其逆转多药耐药性的机制的研究进展。
